Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FULC

Fulcrum Therapeutics Inc

May 13 • 04:00PM ET

7.35

Dollar change -0.12
Percentage change -1.61	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF SURI IBB DWAS PINK DFAS DFAC DFAT PTH

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	5.26%	Shs Outstand	61.92M	Perf Week	-5.16%
Market Cap	456.80M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	1.18%	Shs Float	58.88M	Perf Month	-2.00%
Income	-99.43M	PEG	-	EPS next Q	-0.43	Inst Own	95.62%	Short Float	5.09%	Perf Quarter	-20.54%
Sales	2.51M	P/S	181.99	EPS this Y	-8.10%	Inst Trans	23.62%	Short Ratio	4.97	Perf Half Y	116.81%
Book/sh	3.80	P/B	1.93	EPS next Y	2.69%	ROA	-35.91%	Short Interest	3.00M	Perf Year	131.13%
Cash/sh	3.43	P/C	2.14	EPS next 5Y	14.30%	ROE	-39.00%	52W Range	2.65 - 13.70	Perf YTD	8.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.09%	ROI	-40.78%	52W High	-46.35%	Beta	2.33
Dividend TTM	-	Quick Ratio	17.71	Sales past 5Y	-1.10%	Gross Margin	100.00%	52W Low	177.36%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	17.71	EPS Y/Y TTM	36.12%	Oper. Margin	-3945.24%	RSI (14)	39.59	Volatility	7.51% 5.54%
Employees	76	Debt/Eq	0.05	Sales Y/Y TTM	-37.95%	Profit Margin	-3961.20%	Recom	1.62	Target Price	13.75
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-4.48%	Payout	-	Rel Volume	3.36	Prev Close	7.47
Sales Surprise	-100.00%	EPS Surprise	1.71%	Sales Q/Q	-100.00%	Earnings	May 13 BMO	Avg Volume	603.04K	Price	7.35
SMA20	0.10%	SMA50	-16.98%	SMA200	15.90%	Trades		Volume	2,026,982	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14
Sep-25-23	Initiated	Goldman	Neutral	$5
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$5 → $14
Aug-22-23	Upgrade	Stifel	Hold → Buy	$4 → $11
May-04-23	Downgrade	Goldman	Buy → Neutral	$9 → $3
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral	$20 → $6
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$11 → $8
Mar-09-23	Downgrade	Stifel	Buy → Hold	$35 → $6
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $8
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy	$11
Mar-08-22	Initiated	Oppenheimer	Outperform	$33
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$12 → $34
Apr-26-21	Resumed	Credit Suisse	Outperform	$26
Mar-22-21	Initiated	Credit Suisse	Outperform	$26
Mar-02-21	Initiated	Stifel	Buy	$18
Oct-16-20	Initiated	Piper Sandler	Overweight	$22
Aug-12-20	Reiterated	H.C. Wainwright	Buy	$28 → $20
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$11

Show Previous Ratings

Today 11:53AM	FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
11:02AM	Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug (Pharmaceutical Technology)
08:45AM	Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment (MT Newswires)
08:32AM	Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ... (GuruFocus.com)
07:47AM	Sanofi gambles $80M on Fulcrums muscular dystrophy drug (BioPharma Dive)
07:23AM	Loading…
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 (GlobeNewswire)
06:00AM	Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
May-09-24 08:00AM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire)
May-08-24 08:00AM	Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology (GlobeNewswire)
May-06-24 08:00AM	Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET (GlobeNewswire)
Mar-28-24 04:05PM	Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-22-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-24 07:00AM	Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -10.92%
Mar-08-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Mar-05-24 08:00AM	Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 09:35AM	Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 09:23PM	Q4 2023 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-20-24 04:01PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET (GlobeNewswire)
Feb-06-24 08:00AM	Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-07-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.13%
Nov-10-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:00AM	Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences (GlobeNewswire) -18.71%
Nov-08-23 03:43PM	Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:03AM	Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com) +19.50%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023 (GlobeNewswire)
Oct-31-23 08:50AM	Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET (GlobeNewswire) +8.66%
08:00AM	Loading…
Sep-22-23 08:00AM	Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-15-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.07%
Sep-07-23 08:00AM	Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Aug-25-23 09:16AM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics (Zacks)
Aug-24-23 10:15AM	Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More (Zacks) -11.02%
08:42AM	Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate (Zacks)
01:35AM	4 big analyst picks: Nvidia racks up 3 new buy calls after blowout numbers (Investing.com)
Aug-22-23 02:02PM	Rebel's Edge - August 22: $M, $DKS, $FULC, and Jalen Carter (TheStreet.com) +38.52%
11:39AM	Fulcrum swings back up after FDA lifts clinical hold (American City Business Journals)
07:00AM	FDA Lifts Clinical Hold on Fulcrum Therapeutics FTX-6058 for Sickle Cell Disease (GlobeNewswire)
Aug-11-23 04:53PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-23 08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023 (GlobeNewswire)
06:55AM	Fulcrum Therapeutics Appoints Chief Financial Officer (GlobeNewswire)
Jul-27-23 07:00AM	Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET (GlobeNewswire)
Jul-10-23 07:00AM	Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology (GlobeNewswire)
Jul-07-23 05:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.64%
Jun-20-23 07:00AM	Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire) +6.00%
Jun-09-23 04:54PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 06:07AM	Fulcrum Therapeutics First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-15-23 11:37PM	Q1 2023 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.31%
08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:05AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer (GlobeNewswire)
May-08-23 04:05PM	Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET (GlobeNewswire) +8.64%
May-05-23 06:06PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-23 01:01PM	Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-07-23 05:00PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-05-23 08:00AM	Fulcrum Therapeutics Announces CFO Resignation (GlobeNewswire) -7.63%
Mar-10-23 05:00PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Mar-09-23 10:06PM	Q4 2022 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -23.00%
08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
Mar-07-23 06:06AM	Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 61% over the last year (Simply Wall St.) +6.03%
Mar-06-23 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET (GlobeNewswire)
Feb-28-23 10:00AM	Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-24-23 12:52PM	Shares of drugmaker Fulcrum pivot down as FDA temporarily halts trial (American City Business Journals) -56.09%
08:00AM	Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease (GlobeNewswire)
Feb-23-23 10:00AM	Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-16-23 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics, Inc. (FULC) Could Surge 71.81%: Read This Before Placing a Bet (Zacks)
Feb-10-23 05:27PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-08-23 05:00PM	Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice (Zacks)
Jan-26-23 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics, Inc. (FULC) Could Rally 73.02%: Here's is How to Trade (Zacks)
Jan-17-23 11:15PM	Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-13-23 05:00PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-23 07:47AM	Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength? (Zacks) +6.83%
Jan-08-23 11:42AM	Vince McMahons return to WWE: hedge funds and C-suites weekly (Investing.com)
Jan-05-23 05:44AM	The Petri Dish: Fulcrum CEO steps down; Moderna cools on mpox vaccine (American City Business Journals) +10.39%
Jan-04-23 07:02AM	Fulcrum Therapeutics Provides Business Update and 2023 Outlook (GlobeNewswire)
07:01AM	Fulcrum Therapeutics Announces CEO Transition (GlobeNewswire)
Dec-05-22 05:21PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-22 09:55AM	Can Fulcrum Therapeutics, Inc. (FULC) Climb 232% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 04:01PM	Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference (GlobeNewswire)
Nov-17-22 11:21AM	We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully (Simply Wall St.) -6.07%
Nov-16-22 09:55AM	Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 232% as Wall Street Analysts Expect? (Zacks)
Nov-11-22 06:33PM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-22 08:35AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.97%
07:18AM	Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 05:00PM	Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer (GlobeNewswire)
Nov-02-22 07:05AM	Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET (GlobeNewswire)
Nov-01-22 05:29PM	Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-22 10:02AM	Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-21-22 09:35AM	Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4 Weeks (Zacks)
Oct-12-22 07:30AM	Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada (GlobeNewswire)
Oct-07-22 05:00PM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-22 06:19AM	Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 10% this week, taking one-year losses to 71% (Simply Wall St.)
Sep-09-22 05:00PM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-22 04:01PM	Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences (GlobeNewswire) -8.12%

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tourangeau Greg	Principal Accounting Officer	May 07 '24	Sale	7.76	236	1,831	11,571	May 09 04:10 PM
Tourangeau Greg	Vice President, Finance	Mar 08 '24	Sale	11.72	4,884	57,219	11,807	Mar 08 06:05 PM
Sapir Alex	See Remarks	Mar 04 '24	Buy	11.35	43,360	492,028	43,360	Mar 05 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FULC

Fulcrum Therapeutics Inc

Upgrade your FINVIZ experience